Founded in 2007 by renowned cardiologist and medical device entrepreneur Dr. John B. Simpson, Avinger develops next-generation catheter-based technologies for the treatment of peripheral artery disease (PAD). Leveraging core competencies in medical device catheter engineering and intravascular Optical Coherence Tomography (OCT), Avinger markets Wildcat and Kittycat catheters, and recently received the CE Mark to market Ocelot, the first ever real-time OCT crossing catheter.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/09/12 | $22,500,000 | Series C | ||
| 12/12/13 | undisclosed |
